Intel plans to invest an additional $15 million in AI chip startup SambaNova, taking its stake to about 9%. The move comes as questions emerge around governance and potential conflicts of interest related to CEO Lip-Bu Tan's ties to SambaNova and other startups. This is a fresh expansion of Intel's involvement in AI infrastructure that has not been highlighted in recent coverage of NasdaqGS:INTC. ...
Intel plans to invest an additional $15 million in AI chip startup SambaNova, taking its stake to about 9%. The move comes as questions emerge around governance and potential conflicts of interest related to CEO Lip-Bu Tan's ties to SambaNova and other startups. This is a fresh expansion of Intel's involvement in AI infrastructure that has not been highlighted in recent coverage of NasdaqGS:INTC. At a share price of $50.38, NasdaqGS:INTC has logged a 27.9% return year to date and a 57.3%...
The California star may have earned an Oscar nomination for her portrayal of Joan Baez in Dylan biopic A Complete Unknown, but as she prepares for her stage debut in Les Liaisons Dangereuses, she says impostor syndrome is still a big problem “I feel like I’m imitating an American accent, but it really is mine,” Monica Barbaro jokes. The actor has spent the morning rehearsing in an English accent f...
The California star may have earned an Oscar nomination for her portrayal of Joan Baez in Dylan biopic A Complete Unknown, but as she prepares for her stage debut in Les Liaisons Dangereuses, she says impostor syndrome is still a big problem “I feel like I’m imitating an American accent, but it really is mine,” Monica Barbaro jokes. The actor has spent the morning rehearsing in an English accent for her stage debut in the National Theatre’s revival of Les Liaisons Dangereuses. During interviews, she says, she switches back. “I feel it’s best to use my own voice.” Today, Barbaro – Oscar-nominated for her portrayal of activist and folk singer Joan Baez in James Mangold’s Bob Dylan biopic A Complete Unknown – is using that voice to reflect on a new chapter as a theatre actor. She is playing Madame de Tourvel, one of literature’s most famous casualties of seduction and manipulation. It’s a daunting challenge, not least because of the role’s formidable lineage, with Juliet Stevenson, Michelle Pfeiffer, Annette Stroyberg and Reese Witherspoon among those who have previously taken it on. “Speaking aloud in a theatre for this big of an audience is new for me,” she says, apprehensively. Continue reading...
Forget bare walls and clean lines. Give me curiosity and obsession. Give me evidence of a life well lived I have a friend whose flat when I visit feels like stepping into someone else’s mind. It’s filled to the absolute brim with stuff: cupboards full of mismatched mugs, chintzy ceramic dogs adorning the shelves, piles of books everywhere and, most impressively, a display case lovingly filled with...
Forget bare walls and clean lines. Give me curiosity and obsession. Give me evidence of a life well lived I have a friend whose flat when I visit feels like stepping into someone else’s mind. It’s filled to the absolute brim with stuff: cupboards full of mismatched mugs, chintzy ceramic dogs adorning the shelves, piles of books everywhere and, most impressively, a display case lovingly filled with dozens of Kinder egg toys. The funny thing is, I always leave feeling calmer than I would in any stripped-back, magazine-ready living room. Clutter gets a bad rap, but in a world where we’re told to optimise and streamline everything, its chaos feels stubbornly human. I think clutter, when done right, can be the clearest sign of a life being well lived. It shows that someone has character, taste and experiences they have grown from. I love seeing homes that look like people actually live in them. The worst feeling is entering someone’s house and being met with completely clear walls and countertops, perfectly matching dinnerware sets and shelves full of pristine, untouched books. It’s like stepping into The Stepford Wives. Robin Craig is a freelance writer and journalist based in London Continue reading...
Nine clubs yet to secure front-of-shirt commercial deals Several may begin the campaign without a shirt sponsor Nine Premier League clubs have yet to secure front-of-shirt commercial deals for next season and 12 have not signed contracts, leading to increasing concerns that several may begin the campaign without a shirt sponsor. The imminent ban on shirt advertising from gambling companies is havi...
Nine clubs yet to secure front-of-shirt commercial deals Several may begin the campaign without a shirt sponsor Nine Premier League clubs have yet to secure front-of-shirt commercial deals for next season and 12 have not signed contracts, leading to increasing concerns that several may begin the campaign without a shirt sponsor. The imminent ban on shirt advertising from gambling companies is having a significant impact on all clubs’ commercial returns, other than those in the big six, with an executive at one club telling the Guardian that the collective loss of income from shirt deals could be as high as £80m next season. Continue reading...
The explosion of online gambling and sports betting, as well as the advertising behind it, is attracting a growing number of young people, most of them boys.
The explosion of online gambling and sports betting, as well as the advertising behind it, is attracting a growing number of young people, most of them boys.
Having "brutally honest conversations" about money can bring couples closer together, says Vivian Tu, a financial educator. She shares questions to ask your partner at every relationship stage.
Having "brutally honest conversations" about money can bring couples closer together, says Vivian Tu, a financial educator. She shares questions to ask your partner at every relationship stage.
Octavian Lazar/iStock via Getty Images Topline Summary and Update When I last took a look at CG Oncology ( CGON ), I reaffirmed a cautious "Buy" sentiment even though the stock had been on the rise for some time. Since then, the stock has continued to climb in value ever higher, to many billions in market cap (at the time of writing). Today, I want to digest what we've seen so far for 2026 with CG...
Octavian Lazar/iStock via Getty Images Topline Summary and Update When I last took a look at CG Oncology ( CGON ), I reaffirmed a cautious "Buy" sentiment even though the stock had been on the rise for some time. Since then, the stock has continued to climb in value ever higher, to many billions in market cap (at the time of writing). Today, I want to digest what we've seen so far for 2026 with CGON's clinical efforts, and give my thoughts as to why I think a decline in stock price is more than likely, despite the positive news the company has shared over the past year and the upcoming catalysts they've signaled. Pipeline Updates Cretostimogene Grenadenorepvec Cretostimogene is CGON's entry into the emerging field of oncolytic virus therapy, which entails delivering viruses designed to replicate only in tumor cells, ultimately targeting them for direct killing by the viral infection and also for an adaptive immune response. The target has not changed; CGON is pursuing approval for cretostimogene in patients with non-metastatic bladder cancer, with updates over 2025 focusing on findings from the single-arm, phase 3 BOND-003 trial, including a cohort of patients in BCG-unresponsive, non-muscle invasive bladder cancer with carcinoma in situ showcasing encouraging complete response rates. More findings from this cohort are anticipated in 2026, which will add to what we know about the durability of response to treatment. CGON anticipates submitting a BLA to seek approval in this group of patients later this year. Arguably, the next major catalyst for CGON will be the presentation of topline data from a pivotal trial of cretostimogene after resection in intermediate-risk non-muscle invasive bladder cancer, PIVOT-006. This brings a readout one year ahead of schedule for the first randomized registrational study in this risk category. CGON is also continuing to work on potential combinations using cretostimogene, with findings from a phase 2 study, CORE-008, expected in the...